Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention

Free Radical Biology and Medicine

Volumn 48, Issue 1, 2010, Pages 98-111

  Chew, Eng Hui ^a   Nagle, Amrita A ^a   Zhang, Yaochun ^a   Scarmagnani, Silvia ^b   Palaniappan, Puvithira ^b   Bradshaw, Tracey D ^c   Holmgren, Arne ^d   Westwell, Andrew D ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antitumor mechanism of action; Chemoprevention; Cinnamaldehyde; Free radicals; Glutathione; Michael acceptor; Selenocysteine; Thioredoxin reductase

Indexed keywords

2 BENZOYLOXYCINNAMALDEHYDE; 2 BENZYLOXYCINNAMALDEHYDE; 2 HYDROXYCINNAMALDEHYDE; 2 METHOXYCINNAMALDEHYDE; 2 PENTOXYCINNAMALDEHYDE; 5 FLUORO 2 HYDROXYCINNAMALDEHYDE; CINNAMALDEHYDE; CINNAMALDEHYDE DERIVATIVE; CINNAMIC ACID; SELENOCYSTEINE; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL STRAIN HCT116; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN INDUCTION; UPREGULATION;

ACROLEIN; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NF-E2-RELATED FACTOR 2; STEREOISOMERISM; THIOREDOXIN-DISULFIDE REDUCTASE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 74149084512     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.10.028     Document Type: Article

References (50)

1. Gromer S., Urig S., and Becker K. The thioredoxin system-from science to clinic. Med. Res. Rev. 24 (2004) 40-89
2. Lillig C.H., and Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid. Redox. Signaling 9 (2007) 25-47
3. Soini Y., Kahlos K., Napankangas U., Kaarteenaho-Wiik R., Saily M., Koistinen P., Paaakko P., Holmgren A., and Kinnula V.L. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin. Cancer Res. 7 (2001) 1750-1757
4. Kahlos K., Soini Y., Saily M., Koistinen P., Kakko S., Paakko P., Holmgren A., and Kinnula V.L. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int. J. Cancer 95 (2001) 198-204
5. Kim S.J., Miyoshi Y., Taguchi T., Tamaki Y., Nakamura H., Yodoi J., Kato K., and Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 11 (2005) 8425-8430
6. Raffel J., Bhattacharyya A.K., Gallegos A., Cui H., Einspahr J.G., Alberts D.S., and Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 142 (2003) 46-51
7. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., and Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 281 (2006) 13005-13008
8. Williams Jr. C.H. Lipoamide dehydrogenase, glutathione reductase, thioredoxin reductase, and mercuric ion reductase-a family of flavoenzyme transhydrogenases. In: Muller F. (Ed). Chemistry and Biochemistry of Flavoenzymes Vol. 3 (1992), CRC Press, Boca Raton 121-211
9. Papp L.V., Lu J., Holmgren A., and Khanna K.K. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signaling 9 (2007) 775-806
10. Sandalova T., Zhong L., Lindqvist Y., Holmgren A., and Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc. Natl. Acad. Sci. USA 98 (2001) 9533-9538
11. Biterova E.I., Turanov A.A., Gladyshev V.N., and Barycki J.J. Crystal structures of oxidized and reduced mitochondrial thioredoxin reductase provide molecular details of the reaction mechanism. Proc. Natl. Acad. Sci. USA 102 (2005) 15018-15023
12. Fritz-Wolf K., Urig S., and Becker K. The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis. J. Mol. Biol. 370 (2007) 116-127
13. Urig S., and Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16 (2006) 452-465
14. Lu J., Chew E.H., and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA 104 (2007) 12288-12293
15. Chew E.H., Lu J., Bradshaw T.D., and Holmgren A. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J. 22 (2008) 2072-2083
16. Brigelius-Flohé R., and Banning A. Part of the series: from dietary antioxidants to regulators in cellular signaling and gene regulation. Sulforaphane and selenium, partners in adaptive response and prevention of cancer. Free Radic. Res. 40 (2006) 775-787
17. Rushmore T.H., Morton M.R., and Pickett C.B. The antioxidant responsive element: activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 266 (1991) 11632-11639
18. Ramos-Gomez M., Kwak M.K., Dolan P.M., Itoh K., Yamamoto M., Talalay P., and Kensler T.W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA 98 (2001) 3410-3415
19. Zhang D.D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 38 (2006) 769-789
20. Li W., and Kong A.N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog. 48 (2009) 91-104
21. Dinkova-Kostova A.T., Holtzclaw W.D., and Kensler T.W. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol. 18 (2005) 1779-1791
22. Fang J., Lu J., and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280 (2005) 25284-25290
23. Lu J., Papp L.V., Fang J., Rodriguez-Nieto S., Zhivotovsky B., and Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 66 (2006) 4410-4418
24. Talalay P., De Long M.J., and Prochaska H.J. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. USA 85 (1988) 8261-8265
25. Dinkova-Kostova A.T., Massiah M.A., Bozak R.E., Hicks R.J., and Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. USA 98 (2001) 3404-3409
26. Arnér E.S.J., Sarioglu H., Lottspeich F., Holmgren A., and Böck A. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J. Mol. Biol. 292 (1999) 1003-1016
27. Jeong H.W., Kim M.R., Son K.H., Han M.Y., Ha J.H., Garnier M., Meijer L., and Kwon B.M. Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1. Bioorg. Med. Chem. Lett. 10 (2000) 1819-1822
28. Arner E.S.J., and Holmgren A. Measurement of thioredoxin and thioredoxin reductase. In: Maines M.D., Costa L.G., Reed D.J., Sassa S., and Sipes I.G. (Eds). Current Protocols in Toxicology, Suppl. 5 (2000), Wiley, New York 7.4.1-7.4.14
29. Dhakshinamoorthy S., and Porter A.G. Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. J. Biol. Chem. 279 (2004) 20096-20107
30. Han D.C., Lee M.Y., Shin K.D., Jeon S.B., Kim J.M., Son K.H., Kim H.C., Kim H.M., and Kwon B.M. 2′-Benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species. J. Biol. Chem. 279 (2004) 6911-6920
31. Wu S.J., and Ng L.T. MAPK inhibitors and pifithrin-alpha block cinnamaldehyde-induced apoptosis in human PLC/PRF/5 cells. Food Chem. Toxicol. 45 (2007) 2446-2453
32. Cenas N., Nivinskas H., Anusevicius Z., Sarlauskas J., Lederer F., and Arnér E.S. Interactions of quinones with thioredoxin reductase: a challenge to the antioxidant role of the mammalian selenoprotein. J. Biol. Chem. 279 (2004) 2583-2592
33. Gasdaska P.Y., Gasdaska J.R., Cochran S., and Powis G. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett. 373 (1995) 5-9
34. Zhong L., Arnér E.S.J., and Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc. Natl. Acad. Sci. USA 97 (2000) 5854-5859
35. Arscott L.D., Gromer S., Schirmer R.H., Becker K., and Williams Jr. C.H. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc. Natl. Acad. Sci. USA 94 (1997) 3621-3626
36. Hintze K.J., Wald K.A., Zeng H., Jeffery E.H., and Finley J.W. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J. Nutr. 133 (2003) 2721-2727
37. Chen Z.H., Saito Y., Yoshida Y., Sekine A., Noguchi N., and Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J. Biol. Chem. 280 (2005) 41921-41927
38. Liao B.C., Hsieh C.W., Liu Y.C., Tzeng T.T., Sun Y.W., and Wung B.S. Cinnamaldehyde inhibits the tumor necrosis factor-alpha-induced expression of cell adhesion molecules in endothelial cells by suppressing NF-kappaB activation: effects upon IkappaB and Nrf2. Toxicol. Appl. Pharmacol. 229 (2008) 161-171
39. Wondrak G.T., Cabello C.M., Villeneuve N.F., Zhang S., Ley S., Li Y., Sun Z., and Zhang D.D. Cinnamoyl-based Nrf2-activators targeting human skin cell photo-oxidative stress. Free Radic. Biol. Med. 45 (2008) 385-395
40. Masutani H., Otsuki R., Yamaguchi Y., Takenaka M., Kanoh N., Takatera K., Kunimoto Y., and Yodoi J. Fragrant unsaturated aldehydes elicit activation of the Keap1/Nrf2 System leading to the up-regulation of thioredoxin expression and protection against oxidative stress. Antioxid. Redox. Signaling 11 (2009) 949-962
41. Ka H., Park H.J., Jung H.J., Choi J.W., Cho K.S., Ha J., and Lee K.T. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett. 196 (2003) 143-152
42. Lee C.W., Hong D.H., Han S.B., Park S.H., Kim H.K., Kwon B.M., and Kim H.M. Inhibition of human tumor growth by 2′-hydroxy- and 2′-benzoyloxycinnamaldehydes. Planta. Med. 65 (1999) 263-266
43. Kwon B.M., Cho Y.K., Lee S.H., Nam J.Y., Bok S.H., Chun S.K., Kim J.A., and Lee I.R. 2′-Hydroxycinnamaldehyde from stem bark of Cinnamomum cassia. Planta. Med. 62 (1996) 183-184
44. Kwon B.M., Lee S.H., Cho Y.K., Bok S.H., So S.H., Youn M.R., and Chang S.I. Synthesis and biological activity of cinnamaldehydes as angiogenesis inhibitors. Bioorg. Med. Chem. Lett. 7 (1997) 2473-2476
45. Moon E.Y., Lee M.R., Wang A.G., Lee J.H., Kim H.C., Kim H.M., Kim J.M., Kwon B.M., and Yu D.Y. Delayed occurrence of H-ras12V-induced hepatocellular carcinoma with long-term treatment with cinnamaldehydes. Eur. J. Pharmacol. 530 (2006) 270-275
46. Kwon B.M., Lee S.H., Choi S.U., Park S.H., Lee C.O., Cho Y.K., Sung N.D., and Bok S.H. Synthesis and in vitro cytotoxicity of cinnamaldehydes to human solid tumor cells. Arch. Pharmacal. Res. 21 (1998) 147-152
47. Kim S.Y., Lee K.J., Shin Y.H., and Lee C.H. Physicochemical properties of 2′-benzoyloxycinnamaldehyde. Int. J. Pharm. 287 (2004) 21-26
48. Lee K., Kwon B.M., Kim K., Ryu J., Oh S.J., Lee K.S., Kwon M.G., Park S.K., Kang J.S., Lee C.W., and Kim H.M. Plasma pharmacokinetics and metabolism of the antitumour drug candidate 2′-benzoyloxycinnamaldehyde in rats. Xenobiotica 39 (2009) 255-265
49. Hong S.H., Kim J., Kim J.M., Lee S.Y., Shin D.S., Son K.H., Han D.C., Sung Y.K., and Kwon B.M. Apoptosis induction of 2′-hydroxycinnamaldehyde as a proteasome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells. Biochem. Pharmacol. 74 (2007) 557-565
50. Park Y.S., Misonou Y., Fujiwara N., Takahashi M., Miyamoto Y., Koh Y.H., Suzuki K., and Taniguchi N. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 327 (2005) 1058-1065